Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 16/20 | 0.48 |
| ▸ | MAOA | P21397 | 16/20 | 0.48 |
| ▸ | MAOB | P27338 | 16/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2401865 | 0.92 | KDM1A (0.46) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL28206522 | 0.89 | KDM1A (0.43) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL5435422 | 0.83 | MAPK1 (0.50) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL28521164 | 0.81 | KDM1A (0.45) | KDM1AMAOAMAOBMAPK1 | |
| SCHEMBL28511550 | 0.81 | KDM1A (0.45) | KDM1AMAOAMAOB | |
| SCHEMBL28519822 | 0.81 | ALDH1A1 (0.40) | MAOAMAOBCYP2C19 | |
| SCHEMBL900614 | 0.81 | KDM1A (0.45) | KDM1AMAOAMAOB | |
| SCHEMBL28524795 | 0.80 | KDM1A (0.51) | KDM1A | |
| SCHEMBL9452686 | 0.80 | KDM1A (0.39) | KDM1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL29430083 | 0.79 | KDM1A (0.47) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | claimed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | claimed |
| EP-1377589-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | claimed |
| WO-2002062804-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2002-08-15 | — | — | WO | claimed |
| CN-112142619-B | 1, 1-cyclopropane dicarboxylic acid amide compound and preparation method and application thereof | 浙江工业大学 | 2023-01-10 | — | — | CN | disclosed |
| CN-112142619-A | 1, 1-cyclopropane dicarboxylic acid amide compound and preparation method and application thereof | 浙江工业大学 | 2020-12-29 | — | — | CN | disclosed |
| WO-2010045095-A1 | COMPOUNDS AND METHODS OF USE | XI NING (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009136663-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | KDM1A 4241/4885MAOA 3677/4885MAOB 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.